cypa strong inhibitors inducers cytochrome subfamily family polypeptide medications moderate 
inhibitor prior treatment kinase therapy received parp mek cdk mtor 
inhibitors prior kinase treatment tyrosine therapy mtor patients use pik 
egfr alk mutation tki exon kinase mutations epidermal receptor treatment